BRISTOL-MYERS SQUIBB COMPANY Sales Revenue, Services, Other (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Sales Revenue, Services, Other (Deprecated 2018-01-31) of $58.00 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-10-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesGross · last filed 2017-10-26
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $58.00M, a 107.14% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $48.00M, a 128.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $52.00M, a 188.89% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $29.00M, a 45.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for fiscal 2016 was $96.00M, a 10.28% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for fiscal 2015 was $107.00M, a 72.63% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for fiscal 2014 was $391.00M, a 41.16% increase from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, other (deprecated 2018-01-31) for fiscal 2013 was $277.00M.
| Period end | Sales Revenue, Services, Other (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Other (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Other (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Other (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $58.00M 10-Q · filed 2017-10-26 | $106.00M derived: sum of 2 quarters · filed 2017-10-26 | $158.00M 10-Q · filed 2017-10-26 | $187.00M derived: sum of 4 quarters · filed 2017-10-26 |
| 2017-06-30 | $48.00M 10-Q · filed 2017-07-27 | $100.00M 10-Q · filed 2017-07-27 | $129.00M derived: sum of 3 quarters · filed 2017-07-27 | $157.00M derived: sum of 4 quarters · filed 2017-10-26 |
| 2017-03-31 | $52.00M 10-Q · filed 2017-04-27 | $81.00M derived: sum of 2 quarters · filed 2017-04-27 | $109.00M derived: sum of 3 quarters · filed 2017-10-26 | $130.00M derived: sum of 4 quarters · filed 2017-10-26 |
| 2016-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $57.00M derived: sum of 2 quarters · filed 2017-10-26 | $78.00M derived: sum of 3 quarters · filed 2017-10-26 | $96.00M 10-K · filed 2017-02-21 |
| 2016-09-30 | $28.00M 10-Q · filed 2017-10-26 | $49.00M derived: sum of 2 quarters · filed 2017-10-26 | $67.00M 10-Q · filed 2017-10-26 | $87.00M derived: sum of 4 quarters · filed 2017-10-26 |
| 2016-06-30 | $21.00M 10-Q · filed 2017-07-27 | $39.00M 10-Q · filed 2017-07-27 | $59.00M derived: sum of 3 quarters · filed 2017-07-27 | $80.00M derived: sum of 4 quarters · filed 2017-07-27 |
| 2016-03-31 | $18.00M 10-Q · filed 2017-04-27 | $38.00M derived: sum of 2 quarters · filed 2017-04-27 | $59.00M derived: sum of 3 quarters · filed 2017-04-27 | $98.00M derived: sum of 4 quarters · filed 2017-04-27 |
| 2015-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $41.00M derived: sum of 2 quarters · filed 2017-02-21 | $80.00M derived: sum of 3 quarters · filed 2017-02-21 | $107.00M 10-K · filed 2017-02-21 |
| 2015-09-30 | $21.00M 10-Q · filed 2016-10-27 | $60.00M derived: sum of 2 quarters · filed 2016-10-27 | $87.00M 10-Q · filed 2016-10-27 | |
| 2015-06-30 | $39.00M 10-Q · filed 2016-07-28 | $66.00M 10-Q · filed 2016-07-28 | ||
| 2015-03-31 | $27.00M 10-Q · filed 2016-04-28 | |||
| 2014-12-31 | $391.00M 10-K · filed 2017-02-21 | |||
| 2013-12-31 | $277.00M 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |